Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Repertoire Immune Medicines
Biotech
Genentech builds autoimmune Repertoire with $765M deal
Genentech will pay Repertoire $35 million upfront and up to $730 million in milestones to develop T-cell-targeted medicines for an autoimmune disease.
Darren Incorvaia
Apr 23, 2025 7:00am
BMS pays $65M to expand Repertoire of autoimmune assets
Apr 29, 2024 6:15am
Flagship unveils Metaphore with $50M to mimic natural chemistry
May 16, 2023 6:00am
UPDATE: Flagship's Repertoire reveals culls, cuts and new CEO
Nov 7, 2022 10:47am
Repertoire nabs ex-Celgene exec as CMO—Chutes & Ladders
Jun 4, 2021 9:30am
Repertoire Immune Medicines nabs ex-Celgene exec as CMO
Jun 3, 2021 8:50am
